JFG
IBRX icon

Jefferies Financial Group’s ImmunityBio IBRX Stock Holding History

Jefferies Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$1.26M – 1588
2024
Q2 		$1.26M Buy
+200,000
New +$1.32M 0.01% 675
2023
Q2 		– Sell
-80,000
Closed -$146K – 1833
2023
Q1 		$146K Buy
+80,000
New +$249K ﹤0.01% 1396

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jefferies Financial Group's IBRX Position: Q2 2026 in Review

Jefferies Financial Group sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 300,000 shares — an estimated $2.3M sold.

Jefferies Financial Group first reported a position in IBRX in Q1 2023 and held it in 3 quarters. The position peaked at $2.3M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Jefferies Financial Group reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 300,000 ImmunityBio shares in Q2 2026, an estimated $2.3M.
  • Jefferies Financial Group first reported a position in ImmunityBio in Q1 2023 and held it in 3 quarters.
  • Jefferies Financial Group's ImmunityBio position peaked at $2.3M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.